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Several CCR5 ligands, including small molecules and monoclonal antibodies (MAbs), are being developed as therapies for infection with
strains of human immunodeficiency virus type 1 (HIV-1) that use CCR5 for entry (R5 viruses). The efficacy of such therapies could be influenced
by inter-individual differences in host factors, such as CCR5 expression levels. To study this, we used peripheral blood mononuclear cells
(PBMCs) from humans and rhesus macaques. The half-maximal inhibitory concentrations (IC50) of the small-molecule CCR5 ligands CMPD167,
UK427,857 and SCH-D, and of the PRO 140 MAb, differ by >2 logs in a donor-dependent manner. We studied this variation by using flow
cytometry to measure CCR5 expression on PBMCs from six of the human donors: the IC50 values of both SCH-D and PRO 140 correlated with
CCR5 expression (R2=0.64 and 0.99, respectively). We also determined the efficacy of the CCR5 ligands against HIV-1 infection of HeLa-
derived cell lines that express CD4 at the same level but vary 2-fold in CCR5 expression (JC.48 and JC.53 cells). The moderately greater CCR5
expression on the JC.53 than the JC.48 cells was associated with proportionately higher median IC50 values for all four CCR5 ligands but not for a
soluble CD4-based inhibitor or a non-nucleoside reverse transcriptase inhibitor. We conclude that differences in CCR5 expression on human
PBMCs, which can be affected by CCL3L1 gene dose, may influence the antiviral potency of CCR5 ligands in vitro, but other host factors are also
likely to be involved. These host factors may affect the clinical activity of CCR5 inhibitors, including their use as topical microbicides to prevent
HIV-1 transmission.
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Several ligands of the CCR5 coreceptor are being evaluated
for their potential use as therapy for infection with human
immunodeficiency virus type 1 (HIV-1) (Westby and van der
Ryst, 2005). They are also under consideration as topical
microbicides to prevent HIV-1 sexual transmission (Veazey et
al., 2005; Klasse et al., 2006). The rationale for such approaches
is that CCR5 serves as the principal entry coreceptor for the
most commonly transmitted strains of HIV-1 that predominate
in the early years of infection (Moore et al., 2004). The binding⁎ Corresponding author.
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doi:10.1016/j.virol.2007.02.022of small molecules, monoclonal antibodies (MAbs) or chemo-
kines (natural or modified) to CCR5 can interfere in several
different ways with how the gp120 subunit of the HIV-1 Env
complex interacts with the same receptor: the small molecules
stabilize a CCR5 configuration that is recognized inefficiently
by gp120, thereby acting as allosteric inhibitors (Billick et al.,
2004; Dragic et al., 2000; Kazmierski et al., 2003; Kenakin,
2004; Seibert et al., 2006; Tsamis et al., 2003; Watson et al.,
2005); MAbs are probably competitive inhibitors that impede
the access of gp120 to CCR5 by a steric mechanism (Lee et al.,
1999; Olson et al., 1999; Siciliano et al., 1999); and chemokines
both down-regulate CCR5 and block gp120 binding competi-
tively or non-competitively (Hartley et al., 2004; Signoret et al.,
1997).
Fig. 1. The efficiency of CCR5 inhibitors against HIV-1 and SHIV infection of
human and macaque PBMC is donor-dependent. Human PBMCs from different
donors were infected with (A) HIV-1 JR-FL or (B) HIV-1 CC 1/85. The IC50
values for the indicated inhibitors were determined and their log values are
plotted on the y axis. Data points obtained with different donor PBMCs are
shown above each inhibitor. In (C), the experiment was of similar design, but
involved infection of Rhesus macaque PBMC by SHIV-162P4. The percentage
inhibition was calculated based on comparison with the average p24
concentration in 12 cultures without inhibitor. Each data point is an average of
2 replicate IC50 determinations derived from different but identical titrations.
Inhibition of HIV-1 JR-FL was tested on PBMC from 27 to 30 donors. Among
these, 20 to 28 gave sigmoid fits withR2>0.7 for the different inhibitors. Only the
IC values based on those fits are shown. Inhibition of HIV-1 CC 1/85 was tested
on PBMC from 14 to 16 donors, and the 10 to 15 IC values based on sigmoid fits
with R2>0.7 are shown. PBMC from 23 to 25 macaques out of 29 gave fits with
R2>0.7. Because of some overlapping data points, not all individual IC50 values
are visible. Thin lines in A, B and C connect data points for each donor.
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now been demonstrated in human clinical trials (Fatkenheuer et
al., 2005; Shen et al., 2004; Westby and van der Ryst, 2005) and
in studies in SIV-infected monkeys (Veazey et al., 2003;
Wolinsky et al., 2004). Significant patient-to-patient (or
monkey-to-monkey) variations in the extent of viral load
reduction have been observed during treatment with the small
molecule inhibitors, but a mean viral load reduction of ∼1.5
logs occurs over a 7–10 day dosing period (Fatkenheuer et al.,
2005; Lalezari et al., 2005; McNicholl and McNicholl, 2006;
Rosario et al., 2005; Veazey et al., 2003; Westby and van der
Ryst, 2005). In the case of the SIV-infected monkeys, given the
similarity of the infecting strain present in each animal, the
variation in response is more likely to be dominated by host
rather than viral factors. Because diverse HIV-1 strains are
present within a patient population, both host and viral factors
probably apply within infected people.
Here, we sought insights into the possible host factors that
might influence the efficacy of CCR5 ligands in vitro. There are
significant inter-individual differences in CCR5 expression, so
one obvious parameter that could influence the efficiency of a
CCR5 ligand is the CCR5 density on target cells. We used flow
cytometry and the 2D7 MAb to measure CCR5 expression on
peripheral blood mononuclear cells (PBMCs) from different
human and macaque donors. At the same time, we determined
whether CCR5 expression levels serve as a variable that
influences the efficacy of small molecule inhibitors (CMPD167,
UK427,857 and SCH-D) and the MAb PRO 140 against HIV-1
or SHIV infection via CCR5. The gp120-binding inhibitor PRO
542 (CD4-IgG2) was also studied for comparison with the
CCR5 ligands, as was, in some experiments, the non- nucleo-
side reverse transcriptase inhibitor Efavirenz that acts against
HIV-1 by an entirely different mechanism. Our results indicate
that although variation in cell-surface CCR5 expression clearly
influences how CCR5 ligands inhibit HIV-1 and SHIV infection
of PBMCs from different human donors in vitro, other as yet
undefined host factors are also operative. One factor that may
affect cell-surface CCR5 expression is the dose of the gene
encoding CCL3L1 (MIP-1αP), an HIV-1-inhibitory natural
chemokine ligand of CCR5 that affects the extent to which
CCR5 is down-modulated.
Results
The efficiency of CCR5 inhibitors against HIV-1 and SHIV
infection of human and macaque PBMC is donor-dependent
We infected PBMCs from 32 human donors with the primary
R5 HIV-1 isolates JR-FL and CC1/85 in the presence of the
small molecule CCR5 ligands CMPD167, UK427,857 and
SCH-D, and the PRO 140 anti-CCR5 MAb, to establish IC50
values for inhibition of infection (Figs. 1A, B). Viral growth
was too low in the PBMC of two donors, one of which was
homozygous for CCR5 Δ32, to allow IC50 determinations. For
the remaining 30 donors, we used subsets according to whether
sufficient numbers of cells were available. As an internal control
and for comparative purposes, we concurrently determined theIC50 values for the CD4-based, gp120-binding inhibitor PRO
542 using the same test viruses and the same donors. The
replication efficiencies (p24 production) of the test viruses
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donors.
However, the replication efficiency did not correlate strongly
with the IC values (R2<0.4). Furthermore, the IC50 values in
themselves varied over a >100-fold range between donors for
the CCR5 inhibitors, and for each of the test viruses. The potency
of PRO 542 against both HIV-1 isolates varied by ∼1 log less
than this. Despite these wide variations, as a general rule we
found that the relative potency of all the CCR5 inhibitors to be
similar in cells from the same donor. However, there were
exceptions: We observed that, sometimes, PBMCs from the
same donor were more (or less) sensitive to a particular CCR5
inhibitor than might have been expected from the pattern
observed with the other inhibitors. This was true of all the
inhibitors: No inhibitor was obviously more or less subject than
the others to the observed donor-dependent variation. A similar
degree of variation was observed when CMPD167 and
UK427,857 were used to inhibit SHIV-162P4 infection of
PBMCs derived from 29 macaques (Fig. 1C). This in vitro
variation may be related to the variable effect of CMPD167 on
viral load among macaques infected with the SHIV-162P4 virus
(Veazey et al., 2003).
Influence of CCR5 expression on sensitivities to CCR5
inhibitors in PBMC from different donors
For the next series of experiments, we studied PBMCs from
six randomly chosen human donors in greater detail. We
determined the IC50 values for inhibition of infection by the
primary R5 HIV-1 isolates SB106, SB119 and AK103 for SCH-
D (as a representative of the small molecule CCR5 inhibitors)
and the PRO 140 MAb (Table 1). Because of the considerable
variation that is inherent to the PBMC assay, we introduced the
following features into our experimental design. First, the
experiment was repeated three times; this allowed the determi-
nation of mean values (p24 production and IC50) for each virus
(and each donor). Second, for each viral strain, we normalized
the p24 and IC50 values as explained in Materials and methods.Table 1
Blood donor
35 53 55
Relative p24 a 1.4±0.017 1.1±0.022 1.
Relative PRO 140 IC50
a 0.81±0.067 0.41±0.12 3.
Relative SCH-D IC50
a 0.78±0.023 1.1±0.59 1.
CD4 b 1200 860 32
CCR5b 54 32 12
CCR5 genotype c A/F2 F2/F2 A
CCL3L1 copy number d 2 6 1
a The normalization and pooling of data for the three viral strains SB106, SB119 and
assays for each viral strain was calculated. This was normalized to the mean value on
and IC50 values among the three strains are shown for each blood donor.
b The median cell-surface expression levels on intact cells, as determined by flow c
case of CCR5. The values represent receptor expression levels on the day of infe
consecutive days yielded similar results.
c CCR5 haplotypes were assigned as described previously (Gonzalez et al., 1999)
d CCL3L1 copy number is the rounded number from the average of three indepenThis normalization enabled us to discern effects on susceptibility
and inhibition that were truly specific to the PBMC donor.
The replication efficiencies of the three test viruses differed
by ∼4-fold between the six donors, as did the IC50 values for
the two inhibitors (Table 1). CCR5 expression on the 6 PBMC
samples varied over a 5-fold range (Figs. 2A–D). The
relationships between CCR5 expression, the efficiency of
HIV-1 infection and the IC50 values for inhibition by SCH-D
and PRO 140 were then investigated (Figs. 2B–D). The
correlation between the mean relative p24 production and
CCR5 expression was weak (R2 =0.56), which implies that
factors other than CCR5 levels might affect susceptibility to
infection and production of progeny virus. The correlation
between the IC50 for PRO 140 and CCR5 expression was strong
(R2 =0.99), in part because of a single high data point. The
correlations were similarly strong for the three individual viral
strains used, with R2 values of 0.99, 0.98 and 0.99. There was
also a moderate correlation between the IC50 for SCH-D and
CCR5 expression (R2 =0.64), but in this case the correlation
varied among the three viral strains (R2 =0.44, 0.21 and 0.76).
The pooling of data among strains appears to help in separating
influences that are purely CCR5-dependent from those that are
contingent upon the properties of the HIV-1 test isolate used.
None of the aforementioned variables was found to correlate
with median fluorescence for CD4 (data not shown). However,
in view of the possibility that CD4 and CCR5 levels might
together influence the efficiency of HIV-1 entry and its
inhibition (Platt et al., 1998), we also compared the production
of p24 with the product of the CD4 and CCR5 median
fluorescence values. For both p24 and the IC50 values for PRO
140, these correlations were weaker than those detected for
CCR5 alone (R2 =0.23 and 0.95, respectively), whereas the
correlation was stronger for the IC50 for SCH-D (R
2 =0.77). The
replication efficiencies did not correlate with the IC50 values
(R2<0.24), but the IC50 values for the two inhibitors were
weakly correlated with each other (R2 =0.49).
We next explored the genetic basis for inter-individual
differences in CCR5 cell surface expression among the six61 67 68
3±0.064 0.36±0.036 1.0±0.053 0.83±0.021
3±0.15 0.16±0.050 0.36±0.046 1.0±0.075
6±0.21 0.54±0.071 0.40±0.014 1.6±0.38
00 3100 1100 4500
0 24 28 43
/F2 A/F2 C/G2 C/E
0 4 4
AK103 were performed as follows. The mean of the three independent replicate
the six donors for each strain. The mean value (±S.E.M.) for these relative p24
ytometry, are given for CCR5+ cells in the case of CD4, and for CD4+ cells in the
ction. Additional FACS analyses of samples from the same cultures on three
.
dent runs.
Fig. 2. The influence of CCR5 expression on the sensitivity to CCR5 inhibitors in PBMC from different donors. PBMCs from six human donors were infected with the
primary HIV-1 isolates SB106, SB119 and AK103. The relative IC50 values for inhibition by PRO 140 and SCH-D were determined (see text). (A) The gating
employed in the flow cytometry analyses is depicted. The population of lymphocytes was gated in the side-versus forward-scatter plot. The CD4+ subpopulation of
lymphocytes (blue in histograms) was then gated. (The red tracing in the histograms represents the isotype control.) The median CCR5 fluorescence intensities of these
CD4+ lymphocytes were used for the correlation. (B) The correlation between mean relative p24 production and CCR5 expression was weak, R2=0.56. (C) The
correlation of PRO 140 IC50 with CCR5 expression was strong, R
2=0.99. (D) The correlation of SCH-D IC50 with CCR5 expression was moderate, R
2=0.64.
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haplotype pairs (genotypes) (Gonzalez et al., 2005) for the six
donors are listed in Table 1. The single donor (#67) who was
heterozygous for the CCR5 Δ32-carrying HHG*2 haplotype
expressed CCR5 at a low level. Otherwise, there was no
obvious association between these genotypes and CCR5
expression in this study (in which the sample size was very
small). In contrast, the copy number of CCL3L1 (the gene
encoding MIP-1αP) (Table 1) correlated negatively but weakly
with CCR5 expression; this was in accord with previous
findings (Gonzalez et al., 2005). The R2 values for the
correlations between the CCL3L1 gene dose and the mean
and median values for cell surface expression of CCR5 on
CD4+ cells were −0.55 and −0.37, respectively. The percentage
of CCR5+ cells among the CD4+ cells also showed a weak
negative correlation with CCL3L1 copy number; the R2 value
was −0.45. There was no association between the IC values for
the two CCR5 ligands and CCR5 genotype. This was an
expected finding in view of the lack of any correlation between
CCR5 genotype and CCR5 expression in the few subjects
studied.Inhibition of infection of HeLa cell lines expressing different
CCR5 levels
We also studied infection of the HeLa cell derivatives JC.48
and JC.53 by HIV-1 JR-FL Env-pseudotyped viruses, and its
sensitivity to inhibition by CMPD167, UK427,857, SCH-D and
PRO 140, and as controls, by PRO 542 and Efavirenz (Fig. 3).
The median fluorescence intensity values for CCR5 expression
on these cells were 4500 for JC.48 and 8700 for JC.53, which is
approximately proportional to 5.0×104 and 1.3×105 molecules
per cell, respectively, as determined by Scatchard analysis of
radio-labeled ligand binding to earlier passages of the same cells
(Platt et al., 1998). These levels of CCR5 expression per cell are
∼100-fold greater than the range typically observed on human
PBMCs. Despite this difference, the IC50 values for the JC.48
cells were not higher than those for the PBMC. However, the
cell surface density of CCR5 rather than the total number of
CCR5 molecules per cell might have the greater influence on
the potency of an inhibitor. HeLa cells are larger than human
CD4+ T-cells (2-fold greater median forward scatter signal by
flow cytometry). Hence the densities of CCR5 on the two cell
Fig. 3. The sensitivity of HIV-1 infection to CCR5 inhibitors in HeLa cell lines
expressing different amounts of CCR5. HeLa cell lines expressing high (JC.53)
or low (JC.48) levels of CCR5 were infected with HIV-1 JR-FL pseudotype
virus. The cells or virus were preincubated with CMPD167, U427,857, SCH-D,
PRO 140, PRO 542 or Efavirenz at a range of concentrations. After 72 h, the
cells were lysed, the luciferase activity was measured and the IC50 values for
inhibition on the two cell lines were determined. The symbols each represent the
ratio of IC50 values on the JC.53 cells over those on the JC.48 cells, calculated
from five independent experiments. Horizontal bars indicate medians.
285T.J. Ketas et al. / Virology 364 (2007) 281–290types are likely to be more similar than the total number of
molecules.
The JC.53/JC.48 IC50 ratios were calculated for all inhibitors
in five independent experiments. The ratios for CMPD167,
UK427,857, SCH-D, PRO 140 and PRO 542 were then each
compared with that for Efavirenz by the one-tailed Mann–
Whitney U test. For Evarirenz and PRO 542, these ratios were
∼1.0, implying that the activity of these inhibitors is CCR5-
independent, as expected. The median JC.53/JC.48 IC50 ratios
for the CCR5 ligands were significantly greater than for
Efavirenz (p=0.016; p=0.0040; p=0.028 and p=0.016,
respectively) but not for PRO 542 (p=0.15). The JC.53/JC.48
IC50 ratios for all the CCR5 ligands, taken together, were also
significantly higher than the ratios for the two CCR5-
independent inhibitors, again taken together (p=0.0002, one-
tailed, Mann–Whitney U test).
Discussion
Our goals in this study were 2-fold. First, to assess the degree
of variation in antiviral potency of CCR5 inhibitors when they
were tested using PBMCs from multiple human donors; second,
to determine whether CCR5 expression levels affected the
potency of the CCR5 inhibitors. Intuitively, there might be
expected to be a linear relationship between CCR5 availability
on the cell surface and the concentration of an inhibitory ligand
required to prevent the receptor from being used by a fixed
amount of HIV-1. More specifically, a greater density of
unoccupied CCR5 in the vicinity of an attached virion would
favor the recruitment of CCR5 into a fusion complex. There is
abundant evidence for donor-dependent variation of CCR5
expression, even among donors who do not possess the CCR5-
Δ32 allele. Early studies identified an ∼20-fold variation in
CCR5 expression on PBMC from human donors who lack this
mutation (Moore, 1997; Wu et al., 1997). Much of this variationis probably attributable to polymorphisms in the non-coding
regions (e.g. promoter) of CCR5, which are known to have a
substantial influence on the rate of disease progression in HIV-1
infected people (Martin et al., 1998; Mummidi et al., 1998).
There are two clear limitations of this study: the first is the
well-known imprecision of the PBMC assay for HIV-1
replication, the second is the limited number of replicate assays
that can be performed using cells from a blood donor sample.
Intra-assay variation of this type when using cells from a single
donor will necessarily blur inter-assay comparisons made using
cells from multiple donors. As outlined above, we took several
steps to minimize intra- and inter-assay variation and the
influence of distinct viral strains; specifically, we conducted
multiple repeat experiments, we pooled data derived from three
different viral strains, and we normalized the data for
comparative purposes. Nonetheless, identifying subtle factors
that could affect the sensitivity of CCR5 inhibitors remains
problematic in the PBMC assay. Within the context of these
limitations, we observed that that the apparent influence of
CCR5 surface expression levels on the inhibitory efficiency of
CCR5 ligands is greater than the influence CCR5 levels have on
the susceptibility of PBMC to infection by R5 viruses.
By comparing human PBMCs with a pair of HeLa-cell-
derived cell-lines that express different amounts of CCR5, part
of the donor-dependent variation in the efficiency of entry
inhibition via CCR5 in PBMC assays could be shown to be
attributable to CCR5 expression. On the lymphocyte cell
surface, CCR5 expression varied over a 5-fold range. The IC50
values, which correlated with the CCR5 expression level, varied
by 20-fold for PRO 140 and by 4-fold for SCH-D. Furthermore,
on the HeLa cells, a 2-fold difference in CCR5 expression
(albeit at a much higher absolute level compared to lympho-
cytes) translated into proportionate differences in median IC50
values specifically for the CCR5 ligands but not the other
inhibitors. Overall, we conclude that unidentified factors other
than CCR5 expression levels (as measured using MAbs like
2D7) are likely to modulate the inhibitory efficiency of CCR5
ligands. The activated PBMCs also vary in CD4 expression
(5-fold in median m.f.i. on CCR5+ cells, Table 1), while the
CD4 levels are the same on the two HeLa cell clones. CD4
expression does not, however, seem to be a strong modulating
influence on inhibitor sensitivity; correlations with IC50 values
did not substantially change when the CCR5 levels were
multiplied by the CD4 levels (we tested these correlations
because, in receptor-transfected HeLa cells, variations in the
surface levels of CCR5 and CD4 have been shown to
compensate for each other's effects on susceptibility (Kuhmann
et al., 2000; Platt et al., 1998)). Nevertheless, we note that
receptor level effects can be interconnected: the soluble CD4-
based, coreceptor-independent inhibitor PRO 542 was some-
what less efficient at blocking infection of the HeLa cells with
the higher CCR5 level than of the cells expressing less CCR5.
As noted above, the CCR5 ligand that probably acts
competitively with Env, i.e. the PRO 140 MAb, had a modestly
stronger dependence on the CCR5 expression level on the CD4+
T cells than a small molecule inhibitor with a non-competitive
mechanism of action. However, no such difference was ob-
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of how small molecule inhibitors might function is likely to be
incomplete, as is our knowledge of how their action is
influenced by donor-specific factors other than simply the
expression of CCR5 protein on the cell surface. For example, in
our flow cytometry assays for CCR5 expression, we used the
generally accepted standard reagent for staining CCR5, the 2D7
MAb. This MAb probably does not react uniformly with all
possible isoforms and conformers of CCR5 that could be
present on the cell surface and relevant to HIV-1 entry. It has
been well documented that different MAbs to different CCR5
epitopes generate different estimates of CCR5 expression on the
surface of PBMC (Lee et al., 1999). Conceivably, how HIV-1,
small molecule inhibitors and 2D7 recognize these different
forms of CCR5 may differ, potentially confounding any
possible correlations. We note, however, that variation in
potency due to unidentified cellular factors applies to both PRO
140 and the small molecules alike. There is a report that the
sensitivity of different HIV-1 strains to small molecule CCR5
ligands varies more than to PRO 140 (Safarian et al., 2006).
This may be because small molecules and MAbs interfere
differently with the entry process: small molecules have been
suggested to block V3-dependent binding to the second
extracellular loop of CCR5, whereas MAbs impede the
recruitment of co-receptors into fusion complexes and con-
formational changes within these complexes (Safarian et al.,
2006). How variation in CCR5 levels affects these different
stages of entry, and their inhibition, requires further study.
Studies in cell lines transfected to stably express different
CCR5 levels have been used to demonstrate that CCR5
expression affects the efficiency of CCR5 ligands. For example,
CCR5 expression was varied on CD4+ T-Rex/CCR5 cells using a
tetracycline-regulated promoter, andmeasured using 2D7. HIV-1
infection efficiency was independent of CCR5 expression, but
lower concentrations of the small molecule CCR5 inhibitor
TAK-779 were required to inhibit infection of the cells
expressing the lowest CCR5 level, compared to the other two
lines (Reeves et al., 2002). Similarly, TAK-779 was found to be
∼15-fold more potent on HeLa-CD4/CCR5 cells bearing a
limiting CCR5 concentration (700–2000 receptors per cell) than
on cells with an excess of CCR5 (10,000–20,000 per cell) (Platt
et al., 2005). A third study compared U87/CD4/CCR5 and NP2/
CD4/CCR5 cells, which are both derived from the astroglioma
lineage (Willey et al., 2005). The CCR5 expression levels were
reported to be “far greater” on the NP2 cells, although no values
were given. The inhibitory concentrations of several different
CCR5 ligands were ∼10-fold higher with the NP2 cells (high
CCR5) compared to the U87 cells (low CCR5), irrespective of
the test virus. Similar results were obtained using HeLa cells
expressing high or low levels of CD4 or CCR5, the potency of the
CCR5 ligands again being inversely proportional to the CCR5
expression level, but independent of CD4 expression. For the
small molecule inhibitor UK400,343, the shift in the inhibition
curves between the high- and low-CCR5 expressing cells was
∼100-fold when CD4 expression was high (Willey et al., 2005).
Our results using human PBMCs are consistent with all the
above observations, but we observed rather smaller effects. Thisis partially because the extent of CCR5 expression on PBMC
from different donors varies over a smaller range than among
some high-CCR5 and low-CCR5 cell lines. A second factor is
the aforementioned assay imprecision that blurs correlations
when PBMC are used, which is a lesser problem with cell line-
based assays.
An additional factor to consider is how much CCR5
expression affects the efficiency of HIV-1 entry, because
CCR5 ligands serve to reduce the effective CCR5 concentration
available on the cell for use by HIV-1. In one early study using
HOS-CD4 cells expressing high or low CCR5 levels, a
moderate (7-fold) difference in CCR5 expression (measured
using 2D7) resulted in a much greater difference (30- to 80-fold)
in the amount of virus produced after a single round of
replication. This difference was attributed to post-entry effects,
and not to alterations in the efficiency of HIV-1 entry (Lin et al.,
2002). However, entry was measured using cytoplasmic p24
uptake, which can be problematic for discriminating between
productive and non-productive infection (Schwartz et al., 1998).
When CCR5 expression on peripheral blood CD4+ T-cells from
HIV-1-infected and control individuals was measured using
quantitative flow cytometry and MAb 2D7, it was found to vary
over a 4–5-fold range (Reynes et al., 2001). On average, cells
from slow progressors expressed less CCR5 than normal
progressors (7400 compared to 11,000 molecules per cell),
while uninfected individuals expressed CCR5 at levels similar
to normal progressors (Reynes et al., 2001). The relationship
between in vivo viral load and ex vivo measurements of CCR5
expression was log-linear in nature, implying that minor
variations in CCR5 expression could have a much greater
effect on virus production. A similar inference can be drawn
from the use of siRNA to silence CCR5 expression in vitro:
again, a linear decrease in CCR5 expression resulted in a
logarithmic decline in HIV-1 infection efficiency (Butticaz et
al., 2003). This observation has implications for the activity of
more conventional inhibitors that bind to CCR5 directly, and by
doing so, reduce the effective concentration of the co-receptor
that is available for usage by HIV-1. An explanation might lie in
the multiplicity of CCR5 proteins required for formation of a
functional fusion complex (Kuhmann et al., 2000).
We detected an inverse association between the copy number
of CCL3L1, but not the CCR5 genotype, and CCR5 expression
levels. This inverse association is consistent with previous
findings (Gonzalez et al., 2005). The CCL3L1 copy number is a
whole-number variable (e.g. zero, one, two copies), whereas
there are a large number of CCR5 genotypes (Gonzalez et al.,
2001). In this light, when the sample size is small, it is easier to
detect an association for CCL3L1 copy number than for CCR5
genotype. Our findings also reinforce the notion that CCL3L1
gene dose might be a key determinant of CCR5 expression
levels, which could therefore not only affect an individual's
susceptibility to HIV-1/AIDS but also inter-individual differ-
ences in responses to new, CCR5-targeted therapies.
Virus-dependent influences on the potency of CCR5
inhibitors in vitro have also been identified. R5 isolates
obtained from early in the course of HIV-1 clinical infection
have been found in some studies, but not in others, to be more
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types, including PBMCs (Gray et al., 2005; Jansson et al., 1999;
Koning et al., 2003; Olivieri et al., 2007; Rusert et al., 2005).
Generally, viruses from early in infection required higher levels
of CCR5 and/or CD4 than those isolated in later years, which
have a reduced dependence on both CD4 and CCR5 levels
(Gray et al., 2005). The dependence of HIV-1 infection on the
extent of CD4 or CCR5 expression on target cells is well
established (Kuhmann et al., 2000; Platt et al., 1998). Overall,
these sets of observations are consistent with the acquisition of
an increased affinity for CCR5 during HIV-1 evolution in an
infected individual, perhaps driven by the preferential loss of
cells expressing higher CCR5 levels. However, the extent to
which virus-specific factors will affect the clinical performance
of CCR5 inhibitors is hard to predict, both in absolute terms and
relative to host-dependent variables. The development of
resistance through viral evolution under drug-selection pressure
will, of course, compromise inhibitor efficacy, but this is a
different topic from the baseline sensitivity issues we are
considering here. Host-dependent variation in CCR5 expression
levels on relevant target cells could also influence the efficiency
with which topically applied CCR5 inhibitors impair the sexual
transmission of HIV-1, if and when they are used as vaginal or
rectal microbicides (Veazey et al. 2005; Klasse et al., 2006).
Materials and methods
Inhibitors and MAbs
The small molecule CCR5 inhibitors CMPD167, UK427,857
and SCH-D have all been described elsewhere (Marozsan et al.,
2005; Tagat et al., 2004; Veazey et al., 2003; Westby and van der
Ryst, 2005). SCH-D and UK427,857 are now known as
vicriviroc and maraviroc, respectively. The PRO 140 MAb
binds to CCR5, whereas PRO 542 is a tetravalent, IgG-fusion
protein that contains the first and second extracellular domains
of CD4 and inhibits HIV-1 infection by binding to gp120
(Allaway et al., 1995; Olson et al., 1999). The NNRTI Efavirenz
was a gift from Bill Olson (Progenics).
Virus isolates
The R5 primary isolate JR-FL was obtained from the NIH
AIDS Reagent Repository (http://www.aidsreagent.org/); CC 1/
85 from Ruth Connor (Connor et al., 1997; Trkola et al., 2002);
SB106, SB119, AK103 from Alexandra Trkola (Rusert et al.,
2005). The simian-human hybrid virus SHIV-162P4 (Harouse
et al., 2001; Tan et al., 1999; Veazey et al., 2003) was obtained
from Ron Veazey and subsequently expanded in macaque
PBMC.
PBMC infectivity assay
Human lymphocytes were prepared from leukopacks
obtained from the New York Blood Center (New York, NY).
The resulting PBMC were depleted of CD8+ cells by use of the
RosetteSep CD8+ cocktail (StemCell Technologies, Vancouver,BC, Canada) during Ficoll density gradient separation, as
specified by the manufacturer. The PBMC were cultured in
lymphocyte medium (LM: RPMI 1640 supplemented with 10%
fetal bovine serum (FBS) (Cellgro, Herndon, VA), 100 μg/ml
Penicillin/Streptomycin, 2 mM L-glutamine and 50 U/ml IL-2
(NIH AIDS Research and Reference Reagent Program,
contributed by Hoffman-LaRoche, Inc.). Equal parts of each
PBMC culture were stimulated with either 5 μg/ml of
phytohemagglutinin (PHA; Sigma, St. Louis, MO) or with
supernatant from the OKT3 hybridoma (anti-CD3 stimulation).
After 3 days, the cells from the two different stimulation
cultures were combined into one culture for each donor. The
PHA and OKT3 were removed by washing and replaced with
lymphocyte medium for the remainder of the time in culture
(Ketas et al., 2003). PBMC from rhesus macaques were isolated
by the same procedure as used for human PBMC, except that
the Ficoll was diluted by 10% with PBS and there was no
depletion of CD8+ cells.
PBMC infectivity assay
After 3 days of stimulation, the washed PBMC were seeded
at 100 μl per well into a 96-well plate (Becton Dickenson) at
1.4×106 cells/ml in LM, then incubated with a CCR5 inhibitor
diluted 5-fold in 10 serial steps, or with media, for 1 h before
addition of virus. For studies with PRO 542, the inhibitor was
mixed with the virus in a separate plate for 1 h before addition of
the mixture to the cells. HIV-1 replication was measured by p24
antigen ELISA on day 7, as previously described (Ketas et al.,
2003). Residual p24 from the input virus was measured and
subtracted. Net p24 production in the test wells was compared
to that in the control wells (no inhibitor, defined as 100%).
Similarly, SHIV replication was measured by p27 antigen
ELISA kit (Zeptometrix, Buffalo, NY), according to the
manufacturer's instructions. The IC50 values were determined
on days 6–14, depending on viral growth in control cultures.
For one series of experiments on PBMC from six donors, the
cells were isolated and stored in aliquots at −80 °C in RPMI
1640 medium containing 50% FBS and 10% dimethyl sulfoxide
(Sigma, St. Louis, MO), to allow subsequent infectivity assays
to be repeated using the same cells. The cells were thawed in an
excess of RPMI 1640 containing 50% FBS, then stimulated and
infected as described above.
Flow cytometric analysis of CD4 and CCR5 on CD8+-depleted
PBMC
CD4 was detected with a PE-conjugated anti-CD4 MAb
(clone SK3, BD Immunocytometry Systems, San Jose, CA),
CCR5 with an APC-conjugated anti-CCR5 MAb (clone 2D7,
BD Pharmingen, San Jose, CA). PE- and APC-conjugated
isotype controls MAbs were obtained from BD Pharmingen.
For staining with MAbs, 1×106 CD8+-depleted PBMC were
suspended in 50 μl of cytometry buffer (RPMI 1640 without
phenol red+10% FBS+0.1% NaN3). An aliquot (10 μl) of each
of the anti-CD4 and anti-CCR5 MAbs or the isotype control
MAbs was added for 1 h at 4 °C. The cells were washed three
288 T.J. Ketas et al. / Virology 364 (2007) 281–290times with 200 μl of cytometry buffer, with a 5 min incubation
at 4 °C prior to each wash. After the final wash, the cells were
resuspended in 200 μl of fixing solution (2% w/v paraformal-
dehyde, 2% w/v sucrose in phosphate buffered saline) and
incubated for 15 min at room temperature before the addition of
200 μl of cytometry buffer. Fixed cells were stored at 4 °C until
they were analyzed on an LSRII cytometer (BD Immunocyto-
metry Systems). All of the samples used in this analysis were
analyzed in the same cytometry run, allowing a direct
comparison the MFI values. The lymphocyte population was
identified on the basis of forward (FSC) and side scatter (SSC)
parameters. The gate was drawn so as to exclude monocytes
(the cells with greater FSC and SSC in Fig. 2A), and typically
included 70% to 80% of total cells. The CD4+ cell population
was identified on the basis of specific staining for CD4 (see Fig.
2A). The broadening of the CD4 peak seen in Fig. 2A was a
likely result of the early time after activation, as it resolved into
a narrow peak at a high MFI by day 5 post activation, similar to
what was seen on unactivated cells (results not shown). The
median fluorescence intensities were calculated within the
FACSDiva software (BD Immunocytometry Systems) for the
CD4+ lymphocyte population, after subtraction of the back-
ground MFI values on cells from the same donor that were
stained with isotype control antibodies. Receptor-expression
levels on PBMC samples were analyzed on the day of infection,
i.e. on day 3 of the culture.
CCR5 and CCL3 genotyping
Genomic DNA was isolated from all the donors by using a
QIAamp DNAmini kit (Qiagen, Valencia, CA). Polymorphisms
in CCR5/CCR2 were detected as described previously (Gon-
zalez et al., 1999), and included the polymorphisms at CCR5-
29, 208, 303, 627, 630, 676, 927 in the CCR5 promoter region,
the CCR5-Δ32 in the CCR5 coding region and the CCR2-64V/
I from the CCR2 coding region. All the sequences for the pri-
mers and probes and methods are available upon request from
Dr. S. K. Ahuja. Haplotypes were assigned as described pre-
viously (Gonzalez et al., 1999). CCL3L1 copy number was
screened as reported elsewhere (Goldstein et al., 2000).
Infection of HeLa cell lines by Env-pseudotyped viruses
The HeLa cell-derived clones JC.48 and JC.53 expressing
CD4 and different levels of CCR5 were a gift from David Kabat
(Platt et al., 1998). HIV-1 JR-FL Env-pseudotyped viruses were
harvested from 293T cells (NIH) co-transfected with the NL-
Luc backbone plasmid (Division of AIDS, National Institute of
Allergy and Infectious Diseases, NIH; contributed by N.
Landau) and the JR-FL env plasmid (Beddows et al., 2005).
The cells or the inoculum viruses were incubated with titrated
inhibitors, as in the PBMC infectivity assay. After 72 h of
culture, the cells were lysed and the luciferase activity analyzed
with the Bright-Glo Luciferase Detection Kit (Invitrogen),
according to the manufacturer's instructions. The experiment
was repeated five times, with all the results being depicted in
Fig. 3.Statistical and mathematical analysis
IC50 values were calculated from sigmoid curve-fits (Prism,
GraphPad). All IC50 data presented fulfill the criterion of
R2>0.7; those in the detailed analysis of six donors had, in
addition, 95%-confidence intervals<10-fold. Correlations were
calculated and statistical comparisons (Mann–Whitney test)
were carried out using Prism (GraphPad).
In the detailed analysis of PBMC infection by the three
primary isolates, SB106, SB119 and AK103, we adopted a
normalization procedure in order to reduce confounding
variation attributable to differences among the stocks of the
three viral strains. Each viral strain was tested in triplicate in
order to control experimental variation. The mean p24 and IC50
values of these three replicates were calculated. Then the mean
p24 and IC50 values among the six PBMC donors were
calculated for each strain. These means were used to normalize
the values for each viral strain. We then pooled these relative
p24 and IC50 values for the three viral strains and calculated a
mean for each donor. We thereby obtained relative donor-
specific values for both susceptibility and inhibition that were
minimally affected by the different contents of infectious virus
in the stocks of the three strains.
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